ClinicalTrials.Veeva

Menu

Capturing Key MG-symptoms Using Smartphone Recordings. (CAPTURE - MG)

L

Leiden University Medical Center (LUMC)

Status

Enrolling

Conditions

Myasthenia Gravis
Fatigue

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT06743490
NL86693.058.24

Details and patient eligibility

About

This study will make use of a cross-sectional design of MG patients and non-MG participants to quantitatively assess key MG symptoms, and to explore the applicability of machine learning algorithms to their measurement.

Full description

Due to the cross-sectional design, participants will only have to visit Leiden University Medical Center (LUMC) once. For patients already treated in the LUMC, we will try to align this visit with a standard clinical appointment.

After inclusion, all baseline data, consisting of demographics, clinical history and a number of questionnaires (four for MG participants, three for non-MG participants), will be collected. The symptom-specific assessments are performed in a standard order, with the most fatiguing task (i.e. proximal arm fatigue static assessment) last. We estimate the visit will take a total of 60 minutes.

This study is considered to be low risk. Withholding pyridostigmine for a limited period is part of standard care of MG (before investigations or clinical assessments) and does not affect long term clinical outcome. MG participants will consent to withhold pyridostigmine for 12 hours prior to the study visit if they are on this treatment and restart it after the visit. As this is a non-interventional, observational study where only questionnaire-based and non-contact digital data are being collected, the only source of marginal risk relates to data protection and confidentiality, including arrangements for the transfer and storage of data. Given it would not be possible to deidentify the digital audio or video data while maintaining the requisite integrity for data analysis, we will seek explicit consent for the sharing of this information in this identifiable format.

Enrollment

225 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Age ≥ 18 years
  2. Ability to understand the requirements of the study and provide written informed consent.

Inclusion Criteria for MG participants only:

  1. A clinical diagnosis of myasthenia gravis (ocular or generalized) as defined by the Dutch national guideline (category "definite" or "probable" MG).
  2. MGFA Clinical Classification of disease severity I-IV.
  3. Subjects have at least one of the symptoms of interest (namely dysarthria, dysphonia, proximal arm fatigue and/or ptosis).

Inclusion Criteria for non-MG participants only

  1. Subjects are not diagnosed with and have no clinical suspicion of MG.
  2. Subjects do not have a medical history of any of the symptoms of interest (namely dysarthria, dysphonia, proximal arm fatigue and/or ptosis).

Exclusion criteria

  1. Not willing to be audio-recorded for the study assessments.
  2. Not willing to be video-recorded for the study assessments.
  3. Subjects currently taking part in a clinical trial of an Investigational Medicinal Product.
  4. Subjects who have used an immediate release pyridostigmine-based medication in the 12 hours prior to their participation and participants on prolonged release pyridostigmine.
  5. Subjects have cognitive or physical limitations that, in the opinion of the investigator, limits the subject's ability to complete study procedures/

Exclusion Criteria for MG participants only:

  1. Subjects with an upper-limb amputation or who are non-verbal.
  2. Subjects with a diagnosed neurological disease resulting in muscle weakness, other than MG.

Exclusion Criteria for non-MG participants only:

1. Limitation of upper limb mobility or speech impairment of any cause.

Trial design

225 participants in 2 patient groups

MG patients
Description:
MG patients with at least one of the symptoms of interest (i.e. dysarthria, dysphonia, proximal arm fatigue and/or ptosis). We aim to include 150 patients with Myasthenia Gravis.
Non-MG participants
Description:
Non-MG participants that do not have a medical history of any of the symptoms of interest. We aim to include 75 controls.

Trial contacts and locations

2

Loading...

Central trial contact

Yvonne JM Campman, MD; Martijn R Tannemaat, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems